Amal Therapeutics raised €2.8M in a Series A round in Mar 2016. The company is based in Gen√®ve, Switzerland. Investors in the round: Boehringer Ingelheim Venture Fund, High-Tech Gr√ºnderfonds (HTGF), VI Partners. Data as of 7 Aug 2026.
Reported in EUR — no conversion. €2.8M
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
This is the company's only recorded round.
